Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study

Gynecologic Oncology

Volumn 132, Issue 2, 2014, Pages 292-298

  Fagö Olsen, Carsten Lindberg ^a   Ottesen, Bent ^a   Kehlet, Henrik ^a   Antonsen, Sofie L ^a   Christensen, Ib J ^a   Markauskas, Algirdas ^b   Mosgaard, Berit J ^a,c   Ottosen, Christian ^a   Soegaard, Charlotte H ^d   Soegaard Andersen, Erik ^e   Hoegdall, Claus ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Neoadjuvant chemotherapy; Ovarian cancer; Overall survival; Primary debulking surgery; Surgical outcome

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; APPENDECTOMY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DENMARK; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HYSTERECTOMY; LAPAROTOMY; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OMENTECTOMY; OPERATION DURATION; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PEROPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY;

NEOADJUVANT CHEMOTHERAPY; OVARIAN CANCER; OVERALL SURVIVAL; PRIMARY DEBULKING SURGERY; SURGICAL OUTCOME;

AGED; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DENMARK; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVORS; TREATMENT OUTCOME;

EID: 84894077956     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.11.035     Document Type: Article

References (39)

1. C.K. Høgdall, L. Taaning, and M.L.S. Nielsen Annual report 2011 The Danish Gynecological Cancer Database 2012 [ http://dgcg.dk/images/ DGCD%20rsrapport%202011.pdf (in Danish)]
2. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
3. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
4. Reuss A. du BA, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
5. G.D. Aletti, S.C. Dowdy, B.S. Gostout, M.B. Jones, C.R. Stanhope, and T.O. Wilson et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer Obstet Gynecol 107 2006 77 85
6. G.D. Aletti, S.C. Dowdy, K.C. Podratz, and W.A. Cliby Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer Am J Obstet Gynecol 197 2007 676 677
7. G.D. Aletti, E.L. Eisenhauer, A. Santillan, A. Axtell, G. Aletti, and C. Holschneider et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment Gynecol Oncol 120 2011 23 28
8. T. Giannopoulos, S. Butler-Manuel, A. Taylor, N. Ngeh, and H. Thomas Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma Eur J Gynaecol Oncol 27 2006 25 28
9. M.A. Glasgow, H. Yu, T.J. Rutherford, M. Azodi, D.A. Silasi, and A.D. Santin et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV) J Surg Oncol 107 2013 195 200
10. J.Y. Hou, M.G. Kelly, H. Yu, J.N. McAlpine, M. Azodi, and T.J. Rutherford et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease Gynecol Oncol 105 2007 211 217
11. M.R. Milam, X. Tao, R.L. Coleman, R. Harrell, R. Bassett, and R.R. Dos et al. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer Int J Gynecol Cancer 21 2011 66 71
12. M.M. Thrall, H.J. Gray, R.G. Symons, N.S. Weiss, D.R. Flum, and B.A. Goff Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer Gynecol Oncol 123 2011 461 466
13. M.J. Worley Jr., S.H. Guseh, J.A. Rauh-Hain, K.A. Williams, M.G. Muto, and C.M. Feltmate et al. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol 129 2013 69 73
14. P.E. Schwartz, T.J. Rutherford, J.T. Chambers, E.I. Kohorn, and R.P. Thiel Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival Gynecol Oncol 72 1999 93 99
15. S. Kang, Y.H. Jong, J.H. Hwang, M.C. Lim, S.S. Seo, and C.W. Yoo et al. Is neo-adjuvant chemotherapy a "waiver" of extensive upper abdominal surgery in advanced epithelial ovarian cancer? Ann Surg Oncol 18 2011 3824 3827
16. H. Zheng, and Y.N. Gao Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer Chin J Cancer Res 24 2012 304 309
17. S.J. Lee, B.G. Kim, J.W. Lee, C.S. Park, J.H. Lee, and D.S. Bae Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery J Obstet Gynaecol Res 32 2006 99 106
18. J.A. Rauh-Hain, N. Rodriguez, W.B. Growdon, A.K. Goodman, D.M. Boruta, and N.S. Horowitz et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer Ann Surg Oncol 19 2012 959 965
19. J.A. Rauh-Hain, C.C. Nitschmann, M.J. Worley Jr., L.S. Bradford, R.S. Berkowitz, and J.O. Schorge et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma Gynecol Oncol 129 2013 63 68
20. J. Sehouli, K. Savvatis, E.I. Braicu, S.C. Schmidt, W. Lichtenegger, and C. Fotopoulou Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis Int J Gynecol Cancer 20 2010 1331 1340
21. J. Morrison, K. Haldar, S. Kehoe, and T.A. Lawrie Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer Cochrane Database Syst Rev 8 2012 CD005343
22. E.N. Everett, A.E. French, R.L. Stone, L.M. Pastore, A.A. Jazaeri, and W.A. Andersen et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer Am J Obstet Gynecol 195 2006 568 574
23. S. Kang, T.J. Kim, S.S. Seo, B.G. Kim, D.S. Bae, and S.Y. Park Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer Gynecol Oncol 120 2011 18 22
24. H. Steed, A.M. Oza, J. Murphy, S. Laframboise, G. Lockwood, and P.D. DE et al. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer Int J Gynecol Cancer 16 Suppl. 1 2006 47 53
25. C.G. Trope, M.B. Elstrand, B. Sandstad, B. Davidson, and H. Oksefjell Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV? Eur J Cancer 48 2012 2146 2154
26. K.A. McLean, C.A. Shah, S.A. Thompson, H.J. Gray, R.E. Swensen, and B.A. Goff Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction Gynecol Oncol 118 2010 43 46
27. M. Luyckx, E. Leblanc, T. Filleron, P. Morice, E. Darai, and J.M. Classe et al. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study Int J Gynecol Cancer 22 2012 1337 1343
28. S. Taskin, M. Gungor, F. Ortac, and D. Oztuna Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer Arch Gynecol Obstet 288 6 Dec. 2013 1399 1403
29. I. Vergote, I. De Wever, W. Tjalma, M. Van Gramberen, J. Decloedt, and P. van Dam Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients Gynecol Oncol 71 1998 431 436
30. R.E. Bristow, and D.S. Chi Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis Gynecol Oncol 103 2006 1070 1076
31. S. Kang, and B.H. Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol 16 2009 2315 2320
32. I. Vergote, C.G. Trope, F. Amant, G.B. Kristensen, T. Ehlen, and N. Johnson et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 2010 943 953
33. L. Kumar, R. Hariprasad, S. Kumar, N. Bhatla, S. Thulkar, and S. Deo et al. Upfront surgery vs neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma (EOC): a randomized study 2010 International Gynecologic Cancer Society (IGCS) Prague Czech Republic [Abstract: 824. (http://www.igcs.org/ Abstract/meeting-2010-824.html)]
34. C.L. Fago-Olsen, B. Ottesen, H. Kehlet, A. Markauskas, B.J. Mosgaard, and C. Ottosen et al. Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences Dan Med J 59 2012 A4477
35. Instructions for referral, diagnostics and control of epithelial ovarian-, fallopian tube-, and primary peritoneal cancer and borderline tumors 2009 The Danish Gynecological Cancer Group [ http://dgcg.dk/images/ retningslinier/Ovarie/Overcanceretningslinier-endelig-291009-Karin-og-it.pdf (in Danish)]
36. H.S. van Meurs, P. Tajik, M.H. Hof, I. Vergote, G.G. Kenter, and B.W. Mol et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial Eur J Cancer 49 15 Oct. 2013 3191 3201
37. M.C. Lim, Y.J. Song, S.S. Seo, C.W. Yoo, S. Kang, and S.Y. Park Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer Onkologie 33 2010 324 330
38. E.L. Eisenhauer, N.R. bu-Rustum, Y. Sonoda, C. Aghajanian, R.R. Barakat, and D.S. Chi The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer Gynecol Oncol 108 2008 276 281
39. J. Hynninen, M. Lavonius, S. Oksa, S. Grenman, O. Carpen, and A. Auranen Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol 128 2013 229 232